TNF superfamily member 9Genealiases: 4-1BB-L · CD137L · TNLG5A
Q-omics provides the consensus-scored TNFSF9 profile across patient tissues and cancer cell-line models. TNFSF9 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TNFSF9 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, TNFSF9 RNA expression shows 14,802 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, KIRC, and TGCT as cancer lineages where TNFSF9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFSF9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFSF9 survival associations across molecular data types. TNFSF9 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFSF9 RNA expression–survival associations across cancer types. High TNFSF9 expression shows unfavorable associations in KIRP, UVM, UCS, MESO and READ, but favorable associations in UCEC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TNFSF9 RNA expression.
This table summarizes TNFSF9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TNFSF9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFSF9 shows higher tumor expression in KIRC, KIRP, HNSC, COAD, THCA and LIHC. The KIRC box plot shows higher TNFSF9 RNA expression in tumor versus normal tissue (log2 FC = +3.284, t-test p < 0.001).
This table shows molecular features associated with TNFSF9 in patient tissues and cancer cell lines. In patient samples, TNFSF9 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFSF9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Leukemia.
